Tag Archives: NSAIDS: Non-Steroidal Anti-Inflammatory Drugs

Preventative Treatment to Reduce Risk of Alzheimer’s Disease, Using Non-Steroidal Anti-Inflammatory Drugs? (NHS Choices / Journal of Alzheimer’s Disease)

Posted on March 31, 2018 by Dementia and Elderly Care News

Summary A recent article suggests that use of nonsteroidal anti-inflammatory drugs (NSAIDs) might help to reduce the risk of developing Alzheimer’s Disease, if prescription were to be commenced years before clinical signs were to develop. An NHS Choices Behind the … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Aβ42, Alzheimer Disease Anti-Inflammatory Prevention, Alzheimer’s Disease Biomarkers, Amyloid Beta (Aβ42), Amyloid Beta Protein, Amyloid Cascade Inflammatory Hypothesis, Amyloid-β (Aβ), Amyloidogenic and Inflammatory Pathways, Aurin Biotech, Aurin Biotech Inc. Ltd. (Vancouver), ß-amyloid, Bazian, Behind the Headlines, Biomarkers, Canada, Critical Appraisals, Dementia Risk Reduction and Prevention, Dementia Saliva Testing (Pilot Study), Diagnosis of Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels, ELISA Method to Determine Aβ42 Levels in Saliva, Fluid Biomarker Analysis, Ibuprofen, Ibuprofen and the Reduced Risk of Alzheimer’s Disease Link, Inflammation, Journal of Alzheimer's Disease, Long-Term Ibuprofen Use, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroinflammation, Non-Invasive Biomarkers, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Preclinical Biomarkers in Alzheimer's Disease, Preventative Interventions, Prevention, Saliva Tests, Salivary Amyloid-β Protein 42 Levels, Salivary Biomarkers | Leave a comment

Further Press Releases and Documents Relating to the 2016 Alzheimer’s Association International Conference (Alzheimer’s Association International Conference)

Posted on August 1, 2016 by Dementia and Elderly Care News

Summary A list of press-releases is available relating to some of the main presentations at the Alzheimer’s Association International Conference, held in Toronto last week. Full Text Link Reference Alzheimer’s Association International Conference® 2016. List of Press Releases. [Toronto. Online]: … Continue reading →

Posted in Antipsychotics, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Statistics, Universal Interest | Tagged 2016 Alzheimer’s Association International Conference (AAIC®2016), ADAPT-FS Research Group, Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study (ADAPT-FS), Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Association, Alzheimer’s Association AAIC Press Office, Alzheimer’s Association International Conference® (AAIC®) 2016, Alzheimer’s Disease and Related Dementias (ADRD) Milestones (United States), Alzheimer’s Disease Research in Ibero America, Amyotrophic Lateral Sclerosis (ALS), Australian Reduction in Use of Antipsychotics in Dementia Care, Avoidable Hospital Admissions, Avoidable Hospitalizations of People With Alzheimer’s Disease: Cost to Medicare (USA), Behavioural and Psychological Symptoms of Dementia (BPSD), Beta-Amyloid PET Imaging, Canadian Research: Advances in Dementia Care, Celecoxib, Celecoxib (Selective COX-2 Inhibitor), Centro de Investigatición y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia-Related Misdiagnosis, Dementia-Related Misdiagnosis (Male), Disclosure, Disclosure of Risk Marker Status, Disclosure Protocols for Disclosing APOE Genotype for Risk of Dementia, Epidemiology of Alzheimer's disease in Ibero America, Estudio Nacional de Salud y Envejecimiento en México (ENASEM), Ethical Challenges in Preclinical Alzheimer’s Disease Studies and Trials, Ethical Considerations, Ethical Dilemmas, Ethics, Ethics and Consent, Eye Tests for Detection of Memory Decline and Dementia, Flanders-Belgian Patient Group, Formal Education and Complex Work (Cognitive Reserve), French Three-City Study, Frontotemporal Lobar Degeneration (FTLD), Genome-Wide Association Studies, Genome-Wide Association Studies (GWAS), Genome-Wide Association Study, Genotyping, Ibero America, International Genomics of Alzheimer's Project (IGAP), Latin America, Low Testosterone and Risk of Dementia, Men Receiving Dementia-Related Misdiagnoses More Than Women, Mild Behavioral Impairment (MBI), Milestones for Care and Support in U.S. National Plan to Address Alzheimer's Disease, Naproxen, Naproxen (Nonselective Cyclooxygenase [COX] Inhibitor), Neurodegeneration, Neurodegenerative Disease Research, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, p.R47H rs75932628 in TREM2 (Encoding the Triggering Receptor Expressed on Myeloid Cells 2 Gene on Chromosome 6p21), Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Reduction of Systematic Sedation in Dementia Care, Research and Development, Research and Innovation, Research Commitment, Risk Prevention, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), SABE (Salud Bienestar y Envejecimiento), Single SNP Associations in Flanders-Belgian AD Cohort, Smell and Eye Tests for Detection of Memory Decline and Dementia, Smell Tests For Detection of Memory Decline and Dementia, SNP rs75932628, Stopping Systemic Sedation, Systemic Sedation, Tau Pathogenesis, Tau Therapeutic Strategies, Testosterone Depletion and Increased Risk of Dementia, Three-City Study, Treating People with Alzheimer’s Disease Increases Survival and Reduces Cost of Care (vs. Non-Treatment), TREM2 R47H as a Risk Factor, USA National Plan to Address Alzheimer's Disease, Vascular Care Intervention To Prevent Dementia | Leave a comment

NICE Eyes on Evidence: Cumulative Index 2013 (NICE Evidence)

Posted on September 12, 2013 by Dementia and Elderly Care News

Summary The NICE Evidence‘s Eyes on Evidence service covers significant new evidence across a range of topics. Here is an alphabetical list of the items, which have appeared so far this year, of broad interest to readers of this information … Continue reading →

Heart Risk Warning Over Painkiller Diclofenac (BBC News / MHRA)

Posted on July 1, 2013 by Dementia and Elderly Care News

Summary The medicines regulator has advised that the painkiller diclofenac should not be used by people with heart problems. A European review found a small increased risk of heart attack and stroke. “The Medicines and Healthcare Products Regulatory Agency (MHRA) said … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), In the News, Pain, Pharmacological Treatments, Quick Insights, Systematic Reviews, UK, Universal Interest | Tagged BBC Health News, Cerebrovascular Disease, Chronic Pain, Congestive Heart Failure, Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Coxibs, Diclofenac, Epidemiology and Statistics, Heart Attack or Stroke, Inflammatory Arthritis, Ischaemic Heart Disease, Lancet, Medicines and Healthcare Products Regulatory Agency (MHRA), Medicines Healthcare Products Regulatory Agency (MHRA), MHRA Drug Safety Updates, Musculoskeletal, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Osteoarthritis, Pain Management, Pain Relief, Peripheral Arterial Disease, Stroke, Systematic Reviews and Meta-Analyses | Leave a comment

High-Dose Painkiller Heart Risk (NHS Choices / BBC News)

Posted on May 30, 2013 by Dementia and Elderly Care News

Summary Commonly-used painkillers, such as ibuprofen and diclofenac, can increase the risk of heart problems slightly if taken in high doses over a long time. This conclusion was arrived at by meta-analysis of data from 639 separate clinical trials. The risks remain … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pain, Quick Insights, Systematic Reviews, UK, Universal Interest | Tagged BBC Health News, Behind the Headlines, Chronic Pain, Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Coxibs, Diclofenac, Epidemiology, Epidemiology and Statistics, Ibuprofen, Inflammatory Arthritis, Lancet, Musculoskeletal, Naproxen, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Osteoarthritis, Pain Management, Pain Relief, Systematic Reviews and Meta-Analyses, University of Oxford | Leave a comment

Aspirin, Steroidal and Non-Steroidal Anti-Inflammatory Drugs for Alzheimer’s Disease?

Posted on March 6, 2012 by Dementia and Elderly Care News

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 8, March 2012]. Summary Inflammatory processes have previously been thought to play a role in the pathogenesis of Alzheimer’s Disease (AD). The authors of … Continue reading →

Posted in For Researchers (mostly), International, Pharmacological Treatments | Tagged Aceclofenac, Acemetacin, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Anti-Inflammatory, Aspirin, Bangkok and Baycrest Centre for Geriatric Care, Betamethasone, Celecoxib, Cortisone, COX-2 Inhibitors, Cyclooxygenase 2 Inhibitor, Deflazacort, Department of Family Medicine: Ramathibodi Hospital, Dexamethasone, Dexibruprofen, Dexketoprofen, Diclofenac Sodium, Diflunisal, Diflusinal, Etodolac, Etoricoxib, Fenbufen, Fenoprofen, Flurbiprofen, Hydrocortisone, Ibuprofen, Indometacin, Indomethacin, Ketoprofen, Lumiracoxib, Mahidol University, Mefenamic, Meloxicam, Methylprednisolone, Nabumetone, Naproxen, Nimesulide, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Old Age Psychiatry: Sussex Partnership NHS Foundation Trust, Piroxicam, Prednisone, Ramathibodi Hospital, Sulindac, Sussex Partnership NHS Foundation Trust, Tenoxicam, Tiaprofenic Acid, Triamcinolone, University of Toronto | Leave a comment

Tag Archives: NSAIDS: Non-Steroidal Anti-Inflammatory Drugs

Preventative Treatment to Reduce Risk of Alzheimer’s Disease, Using Non-Steroidal Anti-Inflammatory Drugs? (NHS Choices / Journal of Alzheimer’s Disease)

Heart Risk Warning Over Painkiller Diclofenac (BBC News / MHRA)

High-Dose Painkiller Heart Risk (NHS Choices / BBC News)

Aspirin, Steroidal and Non-Steroidal Anti-Inflammatory Drugs for Alzheimer’s Disease?

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites